The price of Invesco Ltd. (NYSE: IVZ) closed at $19.09 in the last session, down -1.75% from day before closing price of $19.43. In other words, the price has decreased by -$0.34 from its previous closing price. On the day, 5510468 shares were traded. IVZ stock price reached its highest trading level at $19.22 during the session, while it also had its lowest trading level at $18.83.
We take a closer look at IVZ’s different ratios to gain a better understanding of the stock. In the meantime, Its Debt-to-Equity ratio is 0.74 whereas as Long-Term Debt/Eq ratio is at 0.74.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Credit Suisse on October 26, 2022, Downgraded its rating to Underperform and sets its target price to $11.50 from $13 previously.
On October 19, 2022, Credit Suisse started tracking the stock assigning a Neutral rating and target price of $13.
BMO Capital Markets Downgraded its Outperform to Market Perform on June 13, 2022, whereas the target price for the stock was revised from $25 to $20.
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 14 when MM Asset Management Holding LL bought 827,590 shares for $16.21 per share. The transaction valued at 13,412,668 led to the insider holds 81,332,319 shares of the business.
MM Asset Management Holding LL bought 827,590 shares of IVZ for $13,306,240 on Jun 13. The 10% Owner now owns 80,504,729 shares after completing the transaction at $16.08 per share. On May 10, another insider, Vacheron Terry, who serves as the Chief Accounting Officer of the company, bought 4,000 shares for $17.40 each. As a result, the insider paid 69,600 and bolstered with 10,696 shares of the company.
As of this moment, Invesco’s Price-to-Earnings (P/E) ratio for their current fiscal year is 9.55, and their Forward P/E ratio for the next fiscal year is 11.24. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.35 while its Price-to-Book (P/B) ratio in mrq is 0.80.
Stock Price History:
Over the past 52 weeks, IVZ has reached a high of $25.33, while it has fallen to a 52-week low of $13.20. The 50-Day Moving Average of the stock is 16.26, while the 200-Day Moving Average is calculated to be 18.06.
According to the various share statistics, IVZ traded on average about 5.59M shares per day over the past 3-months and 3.87M shares per day over the past 10 days. A total of 457.00M shares are outstanding, with a floating share count of 367.07M. Insiders hold about 0.10% of the company’s shares, while institutions hold 92.30% stake in the company. Shares short for IVZ as of Oct 13, 2022 were 14.66M with a Short Ratio of 14.71M, compared to 13.54M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 3.22% and a Short% of Float of 5.22%.
Dividends & Splits
The forward annual dividend rate for IVZ is 0.75, which was 0.63 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 3.27%, it implies a Forward Annual Dividend Yield of 4.98%. The stock’s 5-year Average Dividend Yield is 5.37. The current Payout Ratio is 35.70% for IVZ, which recently paid a dividend on Dec 01, 2022 with an ex-dividend date of Aug 10, 2022. Stock splits for the company last occurred on Nov 07, 2000 when the company split stock in a 25:10 ratio.
The company has 7 analysts who recommend its stock at the moment. On average, analysts expect EPS of $0.33 for the current quarter, with a high estimate of $0.39 and a low estimate of $0.3, while EPS last year was $0.78. The consensus estimate for the next quarter is $0.34, with high estimates of $0.39 and low estimates of $0.31.
Analysts are recommending an EPS of between $2 and $1.58 for the fiscal current year, implying an average EPS of $1.66. EPS for the following year is $1.75, with 9 analysts recommending between $2.33 and $1.43.
According to 5 analysts, the current quarter’s revenue is expected to be $1.06B. It ranges from a high estimate of $1.08B to a low estimate of $1.05B. As of the current estimate, Invesco Ltd.’s year-ago sales were $1.25B, an estimated decrease of -15.50% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $1.04B, a decrease of -14.50% over than the figure of -$15.50% in the same quarter last year. There is a high estimate of $1.06B for the next quarter, whereas the lowest estimate is $1.02B.
A total of 5 analysts have provided revenue estimates for IVZ’s current fiscal year. The highest revenue estimate was $4.59B, while the lowest revenue estimate was $4.55B, resulting in an average revenue estimate of $4.56B. In the same quarter a year ago, actual revenue was $4.79B, down -4.80% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $4.3B in the next fiscal year. The high estimate is $4.43B and the low estimate is $4.24B. The average revenue growth estimate for next year is down -5.80% from the average revenue estimate for this year.